Egalet (NASDAQ:EGLT) posted its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.11, Morningstar.com reports. The business had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.54 million.
Egalet (NASDAQ EGLT) opened at $0.84 on Wednesday. The company has a quick ratio of 2.68, a current ratio of 2.73 and a debt-to-equity ratio of -3.43. Egalet has a 1 year low of $0.67 and a 1 year high of $5.60.
Several research analysts have weighed in on EGLT shares. Cantor Fitzgerald set a $7.00 price objective on Egalet and gave the stock a “buy” rating in a research report on Thursday, November 16th. Stifel Nicolaus cut Egalet from a “buy” rating to a “hold” rating and set a $1.50 price objective on the stock. in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $5.50.
Egalet Company Profile
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Receive News & Ratings for Egalet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet and related companies with MarketBeat.com's FREE daily email newsletter.